Alterity Therapeutics is a clinical-stage Australian biotech focused on developing treatments for neurodegenerative diseases, with no approved products and no commercial revenue. Alterity's entire pipeline centers on ATH434, a small molecule "iron chaperone" designed to bind and redistribute excess reactive iron in the brain, which drives the toxic protein clumping characteristic of Parkinson's-related disorders. Alterity's primary target indication is Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder affecting roughly 50,000 people in the U.S. with no approved disease-modifying treatments. ATH434 has completed two Phase 2 trials in MSA: a 77-patient randomized controlled trial that showed statistically significant slowing of clinical progression at the 50 mg dose, and an open-label biomarker study in more advanced patients that showed disease progression roughly halved compared to historical controls. Both studies showed neuroimaging evidence of reduced iron accumulation in MSA-affected brain regions. ATH434 holds FDA Fast Track and Orphan Drug designations in both the U.S. and EU. Beyond ATH434, Alterity has a preclinical library of over 1,000 compounds targeting metal-protein interactions, though none are active candidates. Alterity funds operations through equity raises and research grants, outsourcing lab work primarily to the University of Melbourne. The company's path to value runs through either partnering or out-licensing ATH434 to a larger pharma company in exchange for upfront payments, milestones, and royalties, or seeking regulatory approval and commercializing ATH434 with a commercial partner.